Description
The purpose of this study is to determine if patiromer treatment of subjects who developed hyperkalemia while receiving RAASi medications will result in continued use of RAASi medications in accordance with heart failure (HF) treatment guidelines and thereby decrease the occurrence of the combined endpoint of cardiovascular (CV) death and CV hospitalization events compared with placebo treatment.
SIMR (Sacramento/Valley Area) Please contact Debora Holmes-Rees at simr@sutterhealth.org about DIAMOND
View study details on ClinicalTrials.govPrincipal Investigator
Co-Investigator(s)
Recruitment Status
Active, Not Recruiting
Funder
Relypsa
Related Studies
Heart Failure Prevention "2 of 3 Study".
Investigators: Craig Ruggles, M.D., Francisco Prieto, MD, Andrew Hudnut, MD
Interagency Registry for Mechanically Assisted Circulatory Support
Investigator: Robert Kincade, M.D., FACS
Interpretable Deep Learning Model for Longitudinal Electronic Health Record and Applications to Heart Failure Prediction
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator